170 related articles for article (PubMed ID: 36174602)
1. Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
Bösch J; Rugg C; Schäfer V; Lichtenberger P; Staier N; Treichl B; Rajsic S; Peer A; Schobersberger W; Fries D; Bachler M
Semin Thromb Hemost; 2022 Oct; 48(7):850-857. PubMed ID: 36174602
[TBL] [Abstract][Full Text] [Related]
2. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
Stattin K; Lipcsey M; Andersson H; Pontén E; Bülow Anderberg S; Gradin A; Larsson A; Lubenow N; von Seth M; Rubertsson S; Hultström M; Frithiof R
J Crit Care; 2020 Dec; 60():249-252. PubMed ID: 32920503
[TBL] [Abstract][Full Text] [Related]
3. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
4. Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial.
Wang C; Ning YC; Song LP; Li PJ; Wang FH; Ding MX; Jiang L; Wang M; Pei QQ; Hu SM; Wang H
BMJ Open; 2023 Oct; 13(10):e069742. PubMed ID: 37880168
[TBL] [Abstract][Full Text] [Related]
5. Bioactivity of enoxaparin in critically ill patients with normal renal function.
Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
[TBL] [Abstract][Full Text] [Related]
6. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
7. Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study.
Benes J; Skulec R; Jobanek J; Cerny V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 May; 166(2):204-210. PubMed ID: 34042098
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin for venous thromboembolism prophylaxis in general Intensive Care Unit patients: an anti-factor Xa level-based approach.
Zohar N; Ellis MH; Dichtwald S; Meyer A; Zohar E; Ifrach N
Minerva Anestesiol; 2023 May; 89(5):425-433. PubMed ID: 36326777
[TBL] [Abstract][Full Text] [Related]
9. Low Early Antifactor Xa Target Achievement Rate of Low-Molecular-Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care.
Zhang L; Zhang L; Li P; Liu C; Zheng Q; Wang Y
J Clin Pharmacol; 2023 Jun; 63(6):664-671. PubMed ID: 36739592
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
11. The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition.
Masjedi M; Azadikhah S; Zand F; Asmarian N; Sabetian G; Ostovan M; Naderi-Boldaji V
Acta Haematol; 2023; 146(2):137-143. PubMed ID: 36538914
[TBL] [Abstract][Full Text] [Related]
12. Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit.
Vlot EA; Van den Dool EJ; Hackeng CM; Sohne M; Noordzij PG; Van Dongen EPA
Thromb Res; 2020 Dec; 196():1-3. PubMed ID: 32805623
[TBL] [Abstract][Full Text] [Related]
13. Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019.
Mohamed A; Shemanski SM; Saad MO; Ploetz J; Haines MM; Schlachter AB; Hamarshi MS
Clin Appl Thromb Hemost; 2022; 28():10760296221116350. PubMed ID: 35924413
[No Abstract] [Full Text] [Related]
14. Impact of exogenous antithrombin on low molecular weight heparin anti-Xa activity assays in a pediatric and young adult leukemia and lymphoma cohort with variable antithrombin levels.
Schaefer B; Hausfeld A; Martin M; Steele P; Martin J; Reher SR; Lane A; Luchtman-Jones L
Pediatr Blood Cancer; 2020 Nov; 67(11):e28654. PubMed ID: 32841498
[TBL] [Abstract][Full Text] [Related]
15. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations.
Klein SM; Slaughter TF; Vail PT; Ginsberg B; El-Moalem HE; Alexander R; D'Ercole F; Greengrass RA; Perumal TT; Welsby I; Gan TJ
Anesth Analg; 2000 Nov; 91(5):1091-5. PubMed ID: 11049889
[TBL] [Abstract][Full Text] [Related]
16. [Is monitoring of anti-factor Xa levels required for low molecular weight heparin prophylaxis of venous thromboembolism in critically ill patients?].
Ding M; Ning Y; Song L; Li P; Xie F; Li S; Wang C
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 May; 36(5):461-464. PubMed ID: 38845490
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.
Ribic C; Lim W; Cook D; Crowther M
J Crit Care; 2009 Jun; 24(2):197-205. PubMed ID: 19327323
[TBL] [Abstract][Full Text] [Related]
18. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial.
Robinson S; Zincuk A; Larsen UL; Ekstrøm C; Nybo M; Rasmussen B; Toft P
Crit Care; 2013 Apr; 17(2):R75. PubMed ID: 23601744
[TBL] [Abstract][Full Text] [Related]
20. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
